| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | SR; BCSG1 |
| WB Predicted band size | 13 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SNCG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇与SNCG(γ-突触核蛋白)抗体相关的研究文献摘要概览：
---
1. **文献名称**：**"γ-Synuclein promotes cancer metastasis through inhibition of TNF-α-induced apoptosis"**
**作者**：Jiabin Xu, et al.
**摘要**：研究开发了特异性识别SNCG的单克隆抗体，发现SNCG在乳腺癌细胞中高表达，并通过抑制TNF-α信号通路促进肿瘤转移。抗体被用于检测SNCG在肿瘤组织中的定位及表达水平。
---
2. **文献名称**：**"γ-Synuclein interacts with α-synuclein in Parkinson's disease pathology"**
**作者**：Alimova YN, et al.
**摘要**：利用多克隆SNCG抗体，揭示了SNCG与α-突触核蛋白的相互作用在帕金森病神经元变性中的作用，表明SNCG可能通过调控α-突触核蛋白聚集参与疾病进程。
---
3. **文献名称**：**"Gamma-synuclein as a prognostic biomarker in breast cancer"**
**作者**：Liu H, et al.
**摘要**：通过免疫组化(使用抗SNCG抗体)分析乳腺癌患者样本，发现SNCG高表达与淋巴结转移和不良预后显著相关，提示其作为临床生物标志物的潜力。
---
4. **文献名称**：**"Gamma-synuclein overexpression in gliomas modulates cell proliferation"**
**作者**：Fung KM, et al.
**摘要**：研究使用SNCG特异性抗体检测胶质瘤组织，发现SNCG表达与肿瘤分级和增殖标志物(如Ki-67)正相关，提示其可能成为胶质瘤治疗的靶点。
---
**备注**：以上文献为示例性概括，实际引用时需核实具体来源及发表年份。近年研究可能进一步扩展了SNCG抗体在疾病机制或诊断中的应用。
**Background of SNCG Antibody**
γ-Synuclein (SNCG), a member of the synuclein family, is a small, acidic protein primarily expressed in the nervous system. Unlike α-synuclein (linked to Parkinson’s disease), SNCG is notably upregulated in various cancers, including breast, ovarian, and liver cancers, where it promotes tumor progression, metastasis, and chemoresistance. Its oncogenic role involves interactions with cell cycle regulators, signaling pathways (e.g., PI3K/AKT), and cytoskeletal proteins, enhancing proliferation and invasiveness.
SNCG antibodies are critical tools for detecting and quantifying SNCG expression in research and diagnostics. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study SNCG’s tissue distribution, overexpression in malignancies, and subcellular localization. These antibodies aid in exploring SNCG’s role as a potential biomarker for cancer prognosis or therapeutic targeting.
Most SNCG antibodies are raised against specific epitopes, often in rabbits or mice, and validated for specificity to avoid cross-reactivity with α- or β-synuclein. Commercial antibodies may vary in clonality (monoclonal/polyclonal), conjugation (e.g., HRP, fluorescent tags), and applications. Researchers must verify antibody performance in their experimental systems, as SNCG’s low molecular weight (~13 kDa) and homology to other synucleins pose challenges in assay design.
×
